CAR T-Cell Clinical Research Trials

Trial NumberName of TrialDrug & Link to clinicaltrials.gov
NHL CAR T-cell Clinical Research Trials- September 15, 2021
NSH1170A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells, in Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma JCAR017 NCT02631044
NSH1226 An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma JCAR017 NCT03331198
NSH 1251A Phase 1, Multicenter, Open-Label Study of CC-97540, C19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaCC-97540 NCT04231747
Multiple Myeloma CAR T-cell Clinical Research Trials- September 15, 2021
NSH1216 A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (rrMM) (KarMMa-3)bb2121 NCT03651128
NSH1277 A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High-Risk Newly Diagnosed Multiple Myeloma (KarMMa-4)bb2121 NCT04196491